Drug Profile
Erythropoietin transdermal - Zosano Pharma
Alternative Names: ZP-EPOLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Zosano Pharma
- Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anaemia in USA (Transdermal, Patch)
- 21 Jan 2009 Preclinical trials in Anaemia in USA (Transdermal)